Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

March 12, 2013 - MDS - Diagnosis and Treatment Update

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: March 12, 2013
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
Download: Program Slides
Read: Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture

Topics Covered

  • Myelodysplastic syndromes (MDS)
  • Diagnostic tests for MDS
  • Factors used to develop a plan for treatment
  • Current and emerging therapies for MDS
  • Possible treatment side effects and management
  • The role of clinical trials in the advancement of MDS treatment for patients

Speaker

Gail J. Roboz, MD
Director, Leukemia Program
Associate Professor of Medicine
Weill Medical College of Cornell University
NewYork-Presbyterian Hospital
New York, NY

Questions Asked by the MDS Community 

  • What is the status of research on platelet-stimulating agents?
  • After developing acute myeloid leukemia (AML) and being treated for it, can a patient later develop myelodysplastic syndromes (MDS)?
  • What has been your experience with hypomethylating agents in low risk patients? And in which low risk patients have you used this?
  • What is the relationship between dietary intake of iron and the Procrit® that is used to improve hemoglobin and hematocrit?
  • How is chronic myelomonocytic leukemia (CMML) classified?
  • Is there any information about possible organ damage due to the use of lenalidomide (Revlimid®)?
  • If patients are treated with an allogeneic stem cell transplant, do most people relapse and progress to AML or just relapse with MDS alone?
  • If being treated with azacitidine (Vidaza®), at what point would the hemoglobin level indicate it would be time to look into a different type of treatment?
  • What is the criteria for determining that MDS has converted to AML?
  • What is trisomy 8?
  • If a patient received a diagnosis of MDS after being diagnosed with idiopathic thrombocytopenic purpura (ITP), is the MDS just a progression of the ITP?
  • Could you explain how the disease could be gone after two years of treatment for MDS?
  • Does the need for transfusion increase with the duration of the disease?
  • Should patients be concerned if they have pancytopenia and are currently on Revlimid?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society.

last updated on Thursday, September 11, 2014
btn_sharethis